SIGIRR Downregulation and Interleukin-1 Signaling Intrinsic to Renal Cell Carcinoma.
NFKBIZ
PDL1
SIGIRR
inflammation
interleukin-1
renal cell carcinoma
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
03
2022
accepted:
17
05
2022
entrez:
11
7
2022
pubmed:
12
7
2022
medline:
12
7
2022
Statut:
epublish
Résumé
Renal cell carcinoma is highly inflamed, and tumor cells are embedded into a microenvironment enriched with IL1. While inflammatory pathways are well characterized in the immune system, less is known about these same pathways in epithelial cells; it is unclear if and how innate immune signals directly impact on cancer cells, and if we could we manipulate these for therapeutic purposes. To address these questions, we first focused on the inflammatory receptors belonging to the IL1- and Toll-like receptor family including negative regulators in a small cohort of 12 clear cell RCC (ccRCC) patients' samples as compared to their coupled adjacent normal tissues. Our data demonstrated that renal epithelial cancer cells showed a specific and distinctive pattern of inflammatory receptor expression marked by a consistent downregulation of the inhibitory receptor SIGIRR mRNA. This repression was confirmed at the protein level in both cancer cell lines and primary tissues. When we analyzed
Identifiants
pubmed: 35814450
doi: 10.3389/fonc.2022.894413
pmc: PMC9256934
doi:
Types de publication
Journal Article
Langues
eng
Pagination
894413Informations de copyright
Copyright © 2022 Mantione, Sana, Vilia, Riba, Doglioni, Larcher, Capitanio and Muzio.
Déclaration de conflit d'intérêts
Author MV is employed by Engitix Therapeutics Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Cell. 2021 Nov 8;39(11):1497-1518.e11
pubmed: 34715028
Trends Immunol. 2009 Sep;30(9):439-46
pubmed: 19699681
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Eur Cytokine Netw. 2003 Oct-Dec;14(4):211-8
pubmed: 14715412
J Clin Oncol. 1995 Feb;13(2):482-9
pubmed: 7844609
Nature. 2017 Nov 2;551(7678):110-114
pubmed: 29072292
Lancet. 2016 Feb 27;387(10021):894-906
pubmed: 26318520
Med Oncol. 2006;23(2):245-50
pubmed: 16720925
Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3522-6
pubmed: 14993616
Cancer Res. 2017 Mar 1;77(5):1212-1226
pubmed: 28087600
Clin Cancer Res. 2017 May 1;23(9):2346-2355
pubmed: 27799249
Vitam Horm. 2006;74:301-16
pubmed: 17027520
Eur Urol. 2021 Oct;80(4):393-397
pubmed: 34074559
BMC Bioinformatics. 2013 Apr 15;14:128
pubmed: 23586463
Eur Cytokine Netw. 2017 Jun 1;28(2):63-69
pubmed: 28840837
Urol Int. 2020;104(7-8):533-541
pubmed: 32623437
BMC Bioinformatics. 2015 May 22;16:169
pubmed: 25994840
Clin Cancer Res. 1998 May;4(5):1203-13
pubmed: 9607578
Int J Cancer. 1990 Dec 15;46(6):1001-6
pubmed: 1979067
Cancer Discov. 2018 Sep;8(9):1142-1155
pubmed: 29884728
Cancer Cell. 2021 May 10;39(5):594-596
pubmed: 33861995
Nat Rev Nephrol. 2020 Dec;16(12):721-735
pubmed: 32733094
Cancer Sci. 2008 May;99(5):905-13
pubmed: 18294286
EMBO J. 1990 Jun;9(6):1897-906
pubmed: 2112087
Cancer Cell. 2021 May 10;39(5):632-648.e8
pubmed: 33711273
Br J Cancer. 2002 May 6;86(9):1396-400
pubmed: 11986770
Urol Int. 2012;88(3):277-81
pubmed: 22377628
Blood. 2013 Sep 26;122(13):2242-50
pubmed: 23869088
Nat Commun. 2022 Jan 10;13(1):31
pubmed: 35013217
Cancer Immunol Immunother. 1992;35(2):97-105
pubmed: 1596939
J Transl Med. 2019 May 27;17(1):177
pubmed: 31133033
Nat Biotechnol. 2020 Jun;38(6):675-678
pubmed: 32444850
Cardiovasc Res. 2016 Sep;111(4):373-84
pubmed: 27297888
Cell. 2017 May 4;169(4):736-749.e18
pubmed: 28475899
Cancer Res. 2007 Jul 1;67(13):6017-21
pubmed: 17616656
Future Oncol. 2010 Jan;6(1):149-63
pubmed: 20021215
Cancer. 2007 Sep 15;110(6):1241-7
pubmed: 17639589
Clin Cancer Res. 2007 Oct 1;13(19):5703-9
pubmed: 17908959
J Natl Cancer Inst. 1991 Jan 16;83(2):119-23
pubmed: 1988686
Oncotarget. 2017 Jul 25;8(30):49470-49483
pubmed: 28533483
Eur J Cancer. 1994;30A(2):162-7
pubmed: 8155390
Curr Protoc. 2021 Mar;1(3):e90
pubmed: 33780170
Nature. 2004 Jul 8;430(6996):218-22
pubmed: 15241416
Cancer Med. 2012 Aug;1(1):17-27
pubmed: 23342250
Curr Opin Nephrol Hypertens. 2014 Jan;23(1):93-100
pubmed: 24257157
Urol Oncol. 2015 Feb;33(2):68.e9-16
pubmed: 25241276
FEBS Lett. 1989 Jul 3;250(2):607-10
pubmed: 2787758
Ann Oncol. 2017 Aug 01;28(8):1988-1995
pubmed: 28595336
Br J Cancer. 2015 Aug 11;113(4):626-33
pubmed: 26135896
Cancer Cell. 2021 May 10;39(5):649-661.e5
pubmed: 33711272
Target Oncol. 2016 Apr;11(2):143-8
pubmed: 26429561
Cytokine. 1999 Jun;11(6):389-99
pubmed: 10346978
J Lab Clin Med. 1998 Mar;131(3):261-8
pubmed: 9523851
Science. 2021 Sep 17;373(6561):eabj0486
pubmed: 34529467
Mol Cancer. 2016 Dec 19;15(1):83
pubmed: 27993170
J Urol. 1995 Mar;153(3 Pt 1):844-8
pubmed: 7532240
Clin Cancer Res. 2021 Jan 15;27(2):608-621
pubmed: 33148676
J Mol Med (Berl). 2005 Apr;83(4):258-66
pubmed: 15662540
Am J Transl Res. 2021 Mar 15;13(3):1155-1169
pubmed: 33841646
Gastroenterology. 2010 Aug;139(2):574-85
pubmed: 20416302
BJU Int. 2012 Dec;110(11 Pt B):E771-7
pubmed: 23134582
Blood. 2011 Jul 21;118(3):660-9
pubmed: 21652674
Front Oncol. 2021 Apr 28;11:643065
pubmed: 33996558
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
pubmed: 27141961
Urol Oncol. 2022 Jun;40(6):271.e19-271.e27
pubmed: 35140049
Br J Cancer. 2015 Dec 1;113(11):1581-9
pubmed: 26554658
Immunity. 2014 Nov 20;41(5):815-29
pubmed: 25453823
World J Urol. 2021 May;39(5):1369-1376
pubmed: 33386494
Haematologica. 2017 Nov;102(11):1901-1912
pubmed: 28775123
Eur Urol. 2022 Feb;81(2):134-137
pubmed: 34920897
J Immunother Emphasis Tumor Immunol. 1994 Oct;16(3):211-5
pubmed: 7834120
J Immunother (1991). 1992 Apr;11(3):191-7
pubmed: 1515424
Science. 2018 Aug 10;361(6402):594-599
pubmed: 30093597